NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

MBX Biosciences, Inc. (MBX) Stock Analysis

MBX Biosciences, Inc. (MBX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MBX

$61.72

+$0.30 (+0.49%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MBX with… →

MBX Key Statistics

As of Sep 4, 2026
Trading
Open
$61.00
Previous Close
$61.42
Day's Range
60.60–62.73
52-Week Range
9.63–72.64
Volume
271.80K
Valuation
Market Cap
$2.97B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.37
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$86.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.16M
1-Year Return
+377.71%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
746.52K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MBX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+95.69%
2025+71.13%
2024 (partial year)−22.07%

As of September 4, 2026.

MBX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$86.97M—
2024$0.00−$61.92M—
2023$0.00−$32.56M—
2022$0.00−$26.14M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$98.06M−$86.97M—
2024$0.00—−$68.19M−$61.92M—
2023$0.00—−$35.31M−$32.56M—
2022$0.00—−$25.16M−$26.14M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MBX Valuation vs Biotechnology Median

Median of 656 stocks
MetricMBXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MBX Biosciences, Inc. (MBX) is capitalised at $2.97B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 63.

The 52-week range on file runs from $9.63 to $72.64. The most recent close on file for MBX is $61.72, dated September 4, 2026. That is +$0.30 (+0.49%) against the previous close. The latest close sits 540.91% above that 52-week low.

Financial Health

In fiscal 2025, MBX Biosciences, Inc. reported revenue of $0.00. The same year closed with a net loss of $86.97M. The reported profit margin is 0%. Trailing earnings per share are −2.37.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +377.71%. The stored price history starts on September 13, 2024, and the total return since then is +160.97%. Daily returns over the trailing 2 years annualize to a volatility of 114.1%.

Growth & Income

The record shows no dividend for MBX.

The record holds one complete calendar year, 2025, which returned +71.13%. So far in 2026 the price is +95.69%.

Peer Comparison

MBX Biosciences, Inc. (MBX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MBX Biosciences, Inc. MBX $2.97B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MBX Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MBX Biosciences, Inc.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Visit website →